Initial Statement of Beneficial Ownership (3)
September 09 2019 - 1:06PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Libby Peter |
2. Date of Event Requiring Statement (MM/DD/YYYY)
7/10/2019
|
3. Issuer Name and Ticker or Trading Symbol
XBiotech Inc. [XBIT]
|
|
(Last)
(First)
(Middle)
109 LARCH ROAD |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Street)
CAMBRIDGE, MA 02138
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4) | 2. Amount of Securities Beneficially Owned
(Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) | 4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4) | 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) | 6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Director Stock Option | 7/10/2019 | 7/9/2029 | Common Stock | 25000 | $7.76 | D | |
| Explanation of Responses: |
Remarks:
Upon election as a Board Member and pursuant to the Board Member Agreement in place between Peter Libby (the "Reporting Person") and the Company, the Reporting Person was granted non-qualified stock options to purchase 25,000 shares of the Company's common stock on July 10, 2019 (the "Grant Date"). All granted options will be exercisable at a price equal to the closing price of the Company's common stock, as reported by NASDAQ, on the Grant Date, and vest immediately. The Options shall expire ten years from the Grant Date, unless terminated earlier in accordance with the Plan or the Reporting Person's stock option agreement. In accordance with the Plan, the Options will remain exercisable for 90 days after the date of the Reporting Person's termination without cause or resignation. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Libby Peter
109 LARCH ROAD
CAMBRIDGE, MA 02138 | X |
|
|
|
Signatures
|
| /S/ Queena Han under Power of Attorney for Peter Libby | | 9/9/2019 |
| **Signature of Reporting Person | Date |
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024
